A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)
NCT ID: NCT02191917
Last Updated: 2023-01-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
8 participants
OBSERVATIONAL
2014-10-21
2016-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)
NCT02801539
High Dose Inspiratory Muscle Training in LOPD
NCT05431127
Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease
NCT02354664
Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease
NCT05951790
Respiratory Muscle Strength in Patients With NMD
NCT01555905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Measurement of Respiratory Muscle Strength
Respiratory muscle strength measurements by different techniques.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Respiratory muscle strength measurements by different techniques.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented diagnosis with late-onset Pompe disease - At least 18 years of age at study entry
* Willing and able to comply with all study procedures
Exclusion Criteria
* Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the investigator, might compromise patient well-being, study completion, or data collection
* Allergy to tools or procedures used for respiratory muscle testing
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioMarin Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor, MD
Role: STUDY_DIRECTOR
BioMarin Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Royal Brompton Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-002158-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
701-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.